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Hypericin is a potent agent in the photodynamic therapy of cancers. To better understand its tumoritropic behaviour, we evaluated
the major determinants of the accumulation and dispersion of hypericin in subcutaneously growing mouse tumours. A rapid
exponential decay in tumour accumulation of hypericin as a function of tumour weight was observed for each of the six tumour
models investigated, and a similar relationship was found between tumour blood flow and tumour weight. Moreover, there was a
close correlation between the higher hypericin uptake in RIF-1 tumours compared to R1 tumours and tumour vessel permeability. To
define the role of lipoproteins in the transport of hypericin through the interstitial space, we performed a visual and quantitative
analysis of the colocalisation of hypericin and DiOC18-labelled lipoproteins in microscopic fluorescent overlay images. A coupled
dynamic behaviour was found early after injection (normalised fluorescence intensity differences were on the whole less than 10%),
while a shifted pattern in localisation of hypericin and DiOC18 was seen after 24h, suggesting that during its migration through the
tumour mass, hypericin is released from the lipoprotein complex. In conclusion, we were able to show that the tumour accumulation
of hypericin is critically determined by a combination of biological (blood flow, vessel permeability) and physicochemical elements
(affinity for interstitial constituents).
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Photodynamic therapy (PDT) involves the local or systemic
administration of a photosensitising drug that, upon light
irradiation and in the presence of oxygen, results in tumour
destruction (Dolmans et al, 2003). We have recently been focusing
on hypericin, a natural compound isolated from Hypericum plants
(Lavie et al, 1995a), as a potent photosensitiser with a high
antitumoral PDT efficacy (Chen and de Witte, 2000; Chen et al,
2001, 2002). In the course of our study, we found that the
compound accumulated to a large extent in tumour tissues. For
instance, after systemic administration (i.p. 5mgkg
 1 hypericin), a
16-fold higher concentration of hypericin in tumour tissue vs
surrounding healthy tissue (skin, muscle) was found in a
subcutaneous P388 lymphoma tumour model growing in DBA/2
mice (Chen and de Witte, 2000). A fast clearance of hypericin
in the liver, spleen, kidney and plasma was observed within
6h, while the peak concentration of hypericin in the tumour
(maximal 8.7% of the injected dose per gram tissue (% IDg
 1))
occurred at 24–48h after drug administration. To confirm
these data, a study using C3H mice bearing subcutaneous RIF-1
fibrosarcoma tumours was performed. The tumour drug concen-
tration increased rapidly over the initial hours and peaked
(5.5% IDg
 1) approximately 6h after i.v. administration (Chen
et al, 2001).
The tumoritropic characteristics of hypericin, therefore, imply
that some (radio)labelled derivatives of the compound could be
applied in the field of clinical radiodiagnosis, radiotherapy (
131I-
labelled) and possibly also in magnetic resonance imaging (MRI).
In order to better understand the mechanistic background, the
present paper addresses basic aspects and principles of the
accumulation of hypericin in malignant tissue. Previous results
have shown that, compared to normal cells, isolated malignant
cells intrinsically do not take up more hypericin (Kamuhabwa
et al, 2000). Therefore, the tumoritropic behaviour of hypericin
should be envisioned as the result of molecular interactions with
specific in vivo environmental, vascular and tumour tissue
properties. In this paper, the tumour tissue accumulation of
hypericin was examined as a function of tumour weight and a
correlation with tumour perfusion and tumour vessel permeability
was explored. Furthermore, we also investigated the intratumoral
distribution of hypericin and its association with lipoproteins,
aimed at defining the role of lipoproteins as regards the transport
through the interstitial space.
MATERIALS AND METHODS
Animals and tumour system
The following tumour models were used: (a) mouse RIF-1
(radiation-induced fibrosarcoma) cells (kindly provided by Dr F
Stewart, The Netherlands Cancer Institute, The Netherlands)
subcutaneously (s.c.) grafted in female C3H/Km mice, (b) mouse
MH22A hepatoma cells (kindly provided by Dr Z Luksiene,
Institute of Materials Science and Applied Research, Lithuania) s.c.
grafted in female athymic nude mice, (c) human CaCo-2 colon
carcinoma cells (kindly provided by Dr P Augustijns (KU Leuven))
s.c. grafted in female athymic nude mice, (d) human A431 cervix
carcinoma cells (obtained from American Type Culture Collection Revised 31 January 2005; accepted 11 February 2005
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s(ATCC)) s.c. grafted in female athymic nude mice, (e) AY27 TCC
(transitional cell carcinoma) rat cells (originally developed by Drs
S Selman and JA Hampton (Ohio Medical College)) s.c. grafted in
female athymic nude mice and (f) R1 rhabdomyosarcoma rat cells
(kindly provided by Dr W Landuyt (KU Leuven)) s.c. grafted in
female athymic nude mice.
Tumour cells (2 10
6) were inoculated s.c. on the depilated
lower dorsum of female mice (weight range 21–25g, purchased
from Charles River Laboratories (France) or B&K Grimston
(England)). Tumours were grown to different surface diameters
ranging from 2 to 9mm and to thicknesses ranging between 2 and
5mm, as measured by a calliper. These dimensions covered
tumour weights from ca 5 to 200mg.
All aspects of the animal experiment and husbandry were
carried out in compliance with national and European regulations
and were approved by the Animal Care and Use Committee of KU
Leuven.
Statistical analysis was performed using Prism 4.00, GraphPad
Software, San Diego, USA.
Hypericin accumulation in tumour tissue
Tumour-bearing animals were killed 6h after i.v. tail injection of
hypericin (5mgkg
 1). Hypericin (synthesised from emodin
anthraquinone according to Falk et al (1993)) was dissolved in a
mixture of 25% dimethylsulphoxide (DMSO), 25% polyethylene
glycol (PEG) 400 and water (2mgml
 1) immediately before
injection. Tumour tissues were harvested, weighed and frozen at
 201C until determination of the hypericin content. Similar tissue
samples were taken from control mice. Extraction and quantifica-
tion of tissue hypericin concentrations were performed as
previously described (Chen et al, 2001).
Tumour blood perfusion
The RIF-1 and R1 tumour-bearing animals were used to quantify
the tumour perfusion by means of spectrofluorometric determina-
tion of tumour FITC-dextran uptake (fluorescein isothiocyanate
dextran, Mr 2 10
6, obtained from Sigma, St Louis, MO, USA), as
described (Chen et al, 2002).
Tumour vessel permeability
The RIF-1 and R1 tumour-bearing animals were used to assess the
tumour vessel permeability by a modification of the procedure
described by Graff et al (2001). Evans blue dye (Sigma, St Louis,
MO, USA) was dissolved in PBS (5mgml
 1) and injected i.p. in
tumour-bearing mice (25mgkg
 1). After 48h, the animals were
killed and the dissected and weighed tumour tissues dissolved in
1ml of tissue solubiliser (Soluene 350; Packard Industries,
Downers Grove, IL, USA) at 371C overnight. The solution was
allowed to cool before the addition of 2ml of ethyl acetate (Fisher
Scientific, UK) and 2ml of 1 N HCl. Absorption of the upper phase
was read at 626nm using a UV/Visible Spectrophotometer
(Ultrospec 2000 Pharmacia Biotech, Amersham Biosciences,
Uppsala Sweden). Concentrations were determined from a
standard curve of Evans blue dye.
Intratumoral localisation of hypericin and DiOC18
The intratumoral localisation of hypericin and DiOC18 (3,30-
dioctadecyloxacarbocyanine, Molecular Probes Inc., Eugene, OR,
USA) was investigated by i.v. administering hypericin (5mgkg
 1),
immediately followed by DiOC18 (5mgkg
 1) to RIF-1 tumour-
bearing animals (tumour weight range 150–200mg) 5min, 2h, 6h
or 24h before being killed. Prior to injection, DiOC18 was
suspended (2mgml
 1) in 40% propylene glycol, 10% ethanol,
4% Tween 80 and water, after which the mixture was sonicated at
601C for 2h. In another set of experiments, FITC-dextran
(300mgkg
 1, in PBS 30mgml
 1) was administered 2min before
killing the RIF-1 tumour-bearing animals that had received
hypericin (5mgkg
 1).
Tumour samples were immediately mounted in medium (Tissue
Tek embedding medium, Miles Inc., Elkhart, IN 46515, USA) and
immersed in liquid nitrogen. Different serial cryostat sections
(5mM slices) were taken from each tumour. The first of two serial
sections was stained with hematoxylin and eosin (H&E) and the
second was examined by fluorescence microscopy (Axioskop 2
plus equipped with a light-sensitive charge-coupled device digital
camera (Carl Zeiss, Go ¨ttingen, Germany)). To specifically visualise
hypericin, the Zeiss filter set 14 (ex: BP 510–560nm, em: LP
590nm) was used, whereas the distribution of DiOC18 or FITC-
dextran was examined with Zeiss filter set 10 (ex: BP 450–490nm,
em: BP 515–565nm).
Overlay fluorescence images were quantitatively analysed using
a KS imaging software system (Carl Zeiss, Go ¨ttingen, Germany) by
subdividing the images in 2269 square fields of 38.7mM
2 (24 pixels/
field) and by measuring the average fluorescence intensity per field
for hypericin and DiOC18, respectively. The data were normalised
for the maximal fluorescence intensity of each compound, and
expressed as percentage fluorescence intensity (% f.i.). From these
field-by-field data, scattergrams were constructed with axes
representing the % f.i. of each compound. In addition, the
absolute field-by-field differences in fluorescence intensity for
hypericin and DiOC18 (i.e. D¼|(% f.i.hypericin–% f.i.DiOC18)|) were
calculated. The differences were grouped in fractions with
increments of 10% and the percentage of fields corresponding to
each of the fractions was determined. In total, 15 overlay
fluorescence images randomly taken throughout different tumours
(n¼3) were analysed for each time interval.
RESULTS
Tumour accumulation of hypericin
After systemic administration of hypericin, its uptake in tumour
tissue was studied as a function of tumour weight in six tumour
models. As previous results using the RIF-1 tumour model had
demonstrated, a peak concentration of hypericin in tumour tissue
between 4 and 8h after intravenous injection, a 6h interval
between administration and analysis was used in all cases. From
Figure 1 it can be seen that, hinging on the tumour size, large
intratumoral differences in hypericin accumulation exist. Typi-
cally, small tumours tended to accumulate three to four times more
of hypericin relative to their weight, as compared to larger tumours
(ranging from 50 to 200mg). As a matter of fact, for each tumour
model investigated, a rapid exponential decay in hypericin
accumulation was observed from the smallest tumours followed
by a plateau phase, on the average starting from a tumour weight
of 50mg. Of interest, when comparing intertumoral dissimilarities,
a difference in overall tumour accumulation was found between
the mouse RIF-1 fibrosarcoma and rat R1 rhabdomyosarcoma
tumours (see Figure 2).
Tumour blood perfusion and vessel permeability
To further evaluate the intratumoral and intertumoral differences
in hypericin accumulation disclosed in R1 and RIF-1 tumours, we
analysed and compared their relative perfusion as well as their
vessel permeability as a function of tumour weight. To measure
tumour perfusion, FITC-dextran was i.v. injected 2min before the
animal was killed . At this short interval, extravasation of the FITC-
dextran complex is negligible (Shockley et al, 1992) and therefore
the fluorescent tracer is entirely confined to the lumen of the
(tumour) blood vessels. The amount of dye extracted from the
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stumour was expressed as % of the injected dose per gram of
tumour as a function of tumour weight (see Figure 3). Intratumoral
differences similar to the one found in case of the hypericin
accumulation can be seen for both tumour types, that is, a weight-
dependent exponential decay in tumour blood flow followed by a
plateau phase from tumour weights of 50mg on. As there was no
significant difference between RIF-1 and R1 tumours (see Figure 3),
an intertumoral variability in perfusion could not be found.
Tumour vessel permeability was measured by i.p. injection of
Evans blue dye, a dye with a strong affinity for serum albumin.
Extravasation of this dye is based on vessel permeability, which
makes it a good marker for permeability measurements (Graff
et al, 2001). Figure 4 shows the % of injected dose per gram of
tumour vs tumour weight, 48h after administration. Except for
small tumours (o20mg), the relative amount of Evans blue
recovered from one tumour type was similar over a large range of
tumour weight. However, major intertumoral differences between
the permeability of vessels present in RIF-1 and R1 tumours were
found.
Intratumoral localisation of hypericin
To track the intratumoral fate of hypericin, a fluorescence
microscopy study was performed on sections of tumour biopsies
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Figure 1 Accumulation of hypericin, expressed as % of injected dose per gram of tumour, as a function of tumour weight. Animals bearing A431, AY27,
CaCo-2, MH22A, R1 or RIF-1 tumours were killed at 6h after i.v. injection (tail) of hypericin (5mgkg
 1). Data points were fitted using one-phase
exponential decay.
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Figure 2 Comparison of the relative accumulation of hypericin in R1
(’) and RIF-1 tumours (m). The accumulation of hypericin, expressed as
% of injected dose per gram of tumour is shown as a function of tumour
weight. Data points were fitted using one-phase exponential decay. The
logarithm of the amount of hypericin recovered per gram of tumour tissue
as a function of tumour weight is depicted in the inset (for RIF-1:
y¼ 0.001436xþ3.305; for R1: y¼ 0.002194xþ3.015). The data were
statistically compared after linearisation using the two-way ANCOVA test
(analysis of covariance). The difference in relative accumulation of hypericin
in R1 and RIF-1 tumours was extremely significant (P-valueo 0.0001).
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Figure 3 Perfusion of RIF-1 (m) and R1 (’) tumours. The amount
FITC-dextran extracted is expressed as % of injected dose per gram of
tumour, as a function of tumour weight. FITC-dextran (100mgkg
 1) was
i.v. injected 2min before killing. Data points were fitted using one-phase
exponential decay. The logarithm of the amount of FITC-dextran
recovered per gram tumour tissue as a function of tumour weight is
depicted in the inset (for RIF-1: y¼ 0.003575xþ4.408; for R1:
y¼ 0.001982xþ4.273). The data were statistically compared after
linearisation using the two-way ANCOVA test (analysis of covariance).
No significant difference between the perfusion of RIF-1 and R1 tumours
was observed (P-value: 0.064).
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staken at different time points after systemic administration of the
compound to RIF-1 tumour-bearing animals. Since blood-borne
hypericin mainly associates with high-density lipoproteins (HDL)
and other lipoproteins (Chen et al, 2001), it was of interest to verify
whether the compound colocated intratumorally with the lipopro-
teins upon intravenous administration. For that purpose, DiOC18
was simultaneously injected with hypericin into the bloodstream.
DiOC18 is a green fluorescent analogue of DiIC18 (Pitas et al, 1981),
a marker that by means of its very lipophilic C18 moieties avidly
binds to lipoproteins without altering their affinity for the
receptors.
Fluorescence microscopic analysis of tumour tissue, taken
5min, 2, 6 and 24h after administration of the compounds,
revealed a shifting pattern, as a function of time, in the localisation
of labelled lipoproteins and hypericin. At 5min, DiOC18 and
hypericin were still confined to the luminal space of tumoral blood
vessels (Figure 5A), as shown in separate experiments with FITC-
dextran that was injected 2min before killing the animals (results
not shown). Figure 5B shows the situation after 2h, where red
(hypericin) and green (DiOC18) fluorescence are apparent in the
vessels and in the perivascular region. Conversely, at 24h, a more
homogeneous distribution is observed for hypericin in contrast to
DiOC18-labelled lipoproteins that show an irregular spreading
(Figure 5C).
Quantitative measurements of colocalisation of hypericin and
DiOC18 were examined by a field-by-field analysis of fluorescent
overlay images. Scattergrams revealed a good correlation between
the percentage fluorescence intensity of hypericin and DiOC18-
labelled lipoproteins at short intervals after coadministration of
the compounds, whereas a poor correlation was observed at the
later time points (Figure 6). For each time point, the percentage of
fields that fall within fractions of grouped absolute differences (D)
was scored (Figure 7, Table 1). A time-dependent shift in the
distribution among the fractions can be seen, with an increased
amount of larger differences between both compounds at longer
time intervals. For instance, at 5min and 2h, 9276.1 and
8875.6% (mean7s.d.), respectively, of the fields had D values
less than 10%, indicating that at these time points the distribution
of fluorescence between hypericin and DiOC18 was similar.
However, 6h after injection, significantly more fields displayed
higher D values and at 24h the majority of the fields exhibited D
values of more than 10%.
DISCUSSION
A basic understanding of the tumoritropic behaviour of hypericin
would not only support the construction of hypericin derivatives
with optimised PDT characteristics, but also sustain the develop-
ment of labelled derivatives to extend the application of hypericins
beyond the field of PDT. We therefore set out to gain a better
insight in the major determinants of the accumulation and
dispersion of hypericin in tumours.
Our study points out that, at least in the 5–50mg tumour weight
range, the extent of hypericin uptake depends on the tumour
weight, while in larger tumours the uptake remains constant. In the
two models investigated (R1, RIF-1), an identical relationship was
found between tumour blood flow and tumour weight. The fact
that small tumours are relatively better perfused than larger ones
has been documented before (Tozer et al, 1990; Hering et al, 1995).
Since both the hypericin accumulation and the blood flow hinge to
the same extent on the tumour weight, our data suggest that the
hypericin accumulation in tumour tissue is critically dependent on
the extent of local blood perfusion. Consistent with this hypoth-
esis, our fluorescence microscopy analysis of RIF-1 tumour
sections revealed a more homogeneous vessel distribution in small
tumours, with a high percentage of functional vessels and a lack of
necrotic areas. In contrast, large tumours have a more hetero-
geneous vessel distribution, with well-perfused regions in the
periphery and less blood flow in the centrally located viable
tumour regions. As a consequence, hypericin mainly accumulates
in the periphery of these tumours (results not shown). Our results
therefore support the concept that, especially in larger tumours,
the intratumoral blood flow distribution is rather heterogeneous,
both spatially and temporally (Jain, 2001).
Furthermore, we consistently found that the hypericin uptake in
RIF-1 tumours was about twice as high as in R1 tumours. Since
this difference cannot be accounted for by a dissimilar tumour
perfusion, we investigated the permeability of the tumour vessels
involved.
Extravasation of plasma constituents by means of convective
currents across the microvascular wall originates from the
incomplete or totally missing endothelial lining of the rapidly
formed vessels in tumours growing beyond a mass of 10
6 cells
(Feng et al, 2000; Hashizume et al, 2000; Kuszyk et al, 2001). Since
Evans blue accumulated more in RIF-1 than in R1 tumours over a
large tumour weight range, it could be concluded that the larger
amount of marker extravasated in RIF-1 tumours was due to an
increased permeability of the tumour vessels. Hence, it is likely
that the relatively low leakiness of the R1 tumour vessels explains
the lower uptake of hypericin in R1 as compared to RIF-1 tumours.
A similar correlation between tumoral photosensitiser uptake and
tumour vessel permeability has been reported before (Roberts and
Hasan, 1993).
Importantly, it was reported that hypericin binds to human
lipoproteins at high molar ratios (up to 467 and 14moles per
10
4Da of low-density lipoproteins (LDL) and high-density
lipoproteins (HDL), respectively) (Lavie et al, 1995b). In contrast
to human plasma, mouse plasma contains a high HDL/LDL ratio
(Kessel and Woodburn, 1993), so that mainly the hypericin–HDL
complex is formed in the bloodstream of mice (results not shown).
Once extravasated, the lipoproteins tagged with numerous
hypericin molecules become embedded in the tumour interstitial
fluid. At this stage, the hypericin–lipoprotein complexes can
follow two routes leading to hypericin uptake and accumulation in
tumour cells. Firstly, hypericin can comigrate with the lipoprotein
microparticles throughout the interstitial space, followed by
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Figure 4 Extravasation of Evans blue in RIF-1 tumours (m) and R1
tumours (’), expressed as % of injected dose per gram of tumour, as a
function of tumour weight. Data points were fitted using one-phase
exponential decay. The logarithm of the amount of Evans blue recovered
per gram tumour tissue as a function of tumour weight is depicted
in the inset (for RIF-1: y¼ 0.0007355xþ2.116; for R1: y¼ 0.001724x
þ1.826). The data were statistically compared after linearisation using the
two-way ANCOVA test (analysis of covariance). The difference in vessel
permeability in R1 and RIF-1 tumours was extremely significant (P-value
o 0.0001).
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sFigure 5 Fluorescence photomicrographs of 5mm RIF-1 mouse tumour sections sampled at 5min (A), 2h (B) and 24h (C) after i.v. injection of
5mgkg
 1 hypericin (red fluorescence) and 5mgkg
 1 DiOC18-labelled lipoproteins (green fluorescence). Overlay pictures show the combination of
individual photomicrographs of hypericin in the left column, and of DiOC18 in the right column. Scale bar¼100mM.
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sreceptor-mediated intracellular uptake. Of importance here, a
correlation exists between the extent of association of some classes
of photosensitisers with LDL and their efficiency of tumour
targeting (Jori and Reddi, 1993). Alternatively, after collision of the
microparticles with interstitial proteins or tumour cell membranes,
hypericin can be released from the lipoprotein complex, followed
by a lipoprotein-independent diffusion and intracellular uptake of
the compound. A similar in vitro cellular uptake of hypericin in
serum-free conditions has been documented (Siboni et al, 2002).
To investigate which route prevails, lipoproteins were marked
with DiOC18, a compound that virtually irreversibly associates with
lipoproteins. After simultaneous administration of hypericin and
DiOC18 to mice bearing RIF-1 tumours, fluomicroscopic analysis
of tumour sections revealed that both compounds initially behaved
similarly, indicating that hypericin and lipoproteins comigrate.
However, later time intervals showed obvious differences in their
intratumoral localisation. Thus, while the lipoproteins seem to be
limited in their capacity to migrate through the interstitial space,
hypericin spreads rather homogeneously over vascularised areas.
These results suggest that during its migration through the
tumour mass, hypericin is released from the lipoprotein complex.
In support of this notion, it is worth mentioning that unlike the
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Figure 6 Scattergrams representing 2269 field-by-field relationships between normalised fluorescence intensities (% f.i.) of hypericin and DiOC18 at 5min
(r¼0.99) and 24h (r¼0.52) after coadministration of the compounds. Results of representative fluorescent overlay images are shown.
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Figure 7 Time-dependent distribution of percentages of fields as a function of absolute differences (D) between normalised fluorescence intensities (%
f.i.) of hypericin and DiOC18. D Values were grouped in fractions with increments of 10%. Data are expressed as mean7s.d. (average of the analysis of three
tumours and 15 fluorescent overlay images per tumour). Relative field counts for D values between 80 and 100% were zero at all time points. Statistical
analyses of the differences are shown in Table 1.
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slipophilic DiOC18, hypericin is an amphiphilic compound that
preferentially locates to the polar aprotic zone adjacent to the
lipid–water interface (Lenci et al, 1995; Weitman et al, 2001). The
phospholipid moiety in lipoproteins is situated at the surface of the
microparticle, thereby allowing the associated hypericin molecules
to dynamically interact with the immediate surrounding. This
surrounding consists of phospholipid bilayers of plasma mem-
branes of cancer cells and immune cells, and of proteins like
collagen which are abundantly present in the interstitial space
(Jain, 1987). Interestingly, it has been shown that hypericin
associates with collagen resulting in a photodynamic effect, while
another photosensitiser Chlorin e6 was ineffective (Yova et al,
2001).
In conclusion, the results of the present study indicate that the
tumour accumulation of hypericin is critically determined by a
combination of tumour-dependent and compound-dependent
factors. As far as the tumour tissue is concerned, it is clear that
an adequate vascularisation, blood flow and vessel permeability, all
contribute to the ability of hypericin to accumulate in the tumour
mass. On the other hand, once extravasated and locally delivered
by a lipoprotein carrier, the compound itself can dramatically
affect the level of its migration throughout the interstitial zone.
Our study reveals that hypericin may have an affinity for some
constituents typically present in the interstitium, and that there
probably is a partitioning of the compound over lipoproteins,
structural proteins and lipid bilayers of cancer and immune cells.
This partitioning allows hypericin to spread rather homogeneously
over the tumour mass.
The present study shows that hypericin accumulates less in
tumoral sites with a poorly developed or afunctional vascular
system, typical of larger tumours. Of importance, since the plasma
clearance rate of hypericin is fast, following a two-phase
exponential decay with half-lives of only 0.08 and 1.4h (Chen
et al, 2001), prolonging the exposure time of tumour tissue to
blood-borne hypericin, that is by repeated i.v. injections or by
intraperitoneal hypericin pumps, could result in an increased
tumoral uptake and an improved homogeneous diffusion over the
whole tumour mass. This is an interesting possibility, which is
currently under investigation in our laboratory.
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